Dr. Linda Vahdat is seeking women 18 years of age or older, diagnosed with metastatic triple negative breast cancer for a research study.
This clinical trial is for women with metastatic triple negative breast cancer (mTNBC). This means that the three most common types of receptors (estrogen, progesterone, and human epidermal growth factor [HER2]) known to fuel most breast cancer growth are not present in their cancer.
To learn more about the study and to see if you are eligible [go]
The Weill Cornell Breast Center recently opened a new triple negative breast cancer program. The study is for women diagnosed with triple negative breast cancer. There is an urgent need to develop new, targeted treatments for triple negative breast cancer. Through our Program, we plan to integrate research, treatment and education to accelerate and identify new targets and strategies to treat and cure triple negative breast cancer.
For more information about the study, please call Margie for a consult appointment with Dr. Vahdat at (212)-821-0644 and contact Naomi for more information at (212)-821-0984 or email@example.com.
“From a patient perspective this study requires very little of participants. I think that for post-treatment women like me the opportunity to participate so easily in cutting edge research at a world-class institution like WCMC is a great way to ‘pay it forward’ in appreciation to all those women whose participation in past clinical trials directly benefited us in terms of improvements in how breast cancer is treated. This is an exceedingly rare opportunity!”
– Triple Negative Breast Cancer Program participant
In this video series the Weill Cornell Breast Center’s Dr. Linda Vahdat discusses the benefits of clinical trials, misconceptions about clinical trials, questions patients should be asking their doctors, and the role of the internet in clinical trial awareness. Dr. Vahdat is currently enrolling patients in a number of breast cancer clinical trials. Click here to view Dr. Vahdat’s clinical and research profile.